The Lancet Commission on medicine, Nazism, and the Holocaust: historical evidence, implications for today, teaching for tomorrow
By Herwig Czech et al.,
The Lancet
| 11. 08. 2023
Executive Summary
The Holocaust, the systematic, state-sponsored persecution and murder of 6 million Jews by the National Socialist (Nazi) regime and its collaborators, is arguably the most extreme instance of crimes against humanity and genocide in history. During its reign of terror, the Nazi regime committed innumerable acts of violence against Jews, Sinti and Roma, people with disabilities or psychiatric illnesses, political prisoners, prisoners of war, and others. A distinctive and disturbing feature of these atrocities is the important role that health professionals played in formulating, supporting, and implementing inhumane and often genocidal policies. After World War 2, these crimes were important factors that contributed to the establishment of contemporary health professional ethics. Learning about, and reflecting upon, this history can have various benefits for learners and practitioners of health sciences, and the patients and communities they serve. Health sciences curriculums, however, rarely cover this topic. This is why Richard Horton, The Lancet's Editor-in-Chief, convened the Lancet Commission on Medicine, Nazism, and the Holocaust.
Nearly 80 years after the defeat of Nazi Germany and the end of World War...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Rob Stein, NPR | 04.24.2024
Lisa Pisano was lying in a hospital bed at NYU Langone Health, hooked up to beeping monitors and an array of tubes. Her surgical wounds were still healing, and she looked tired. But the 54-year-old New Jersey woman said she...